E
301331
vs
S
Shanghai Composite
Over the past 12 months, Enwei Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +22% compared to the Shanghai Composite's +24% growth.
Stocks Performance
301331 vs Shanghai Composite
Performance Gap
301331 vs Shanghai Composite
Performance By Year
301331 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Enwei Pharmaceutical Co Ltd
Glance View
Enwei Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of proprietary Chinese and chemical medicines. The company is headquartered in Chengdu, Sichuan and currently employs 1,610 full-time employees. The company went IPO on 2022-09-21. The firm focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The firm's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The firm principally conducts its businesses in the domestic market.
